SGLT2 inhibitors have been shown to attenuate podocyte damage and proteinuria in diabetic db/db mice (Tomita et al., 2020) and in nondiabetic chronic kidney disease mice (Cassis et al., 2018). This evidence concerns the gene SLC5A2 and chronic kidney disease.